Publications by authors named "M Del Chiaro"
Purpose: To assess the association between neoadjuvant therapy and overall survival (OS) in patients with left-sided resectable pancreatic cancer (RPC) compared to upfront surgery.
Background: Left-sided pancreatic cancer is associated with worse OS compared to right-sided pancreatic cancer. Although neoadjuvant therapy is currently seen as not effective in patients with RPC, current randomized trials included mostly patients with right-sided RPC.
Doping prevention transcends elite sports, highlighting a broader societal challenge where performance enhancement is driven by pressures to increase strength, beauty, and status. This issue extends to adolescents and non-competitive sports participants, where self-optimization pressures are increasingly normalized. Research underscores the need for tailored educational interventions that go beyond punitive measures, fostering ethical decision-making and personal responsibility.
View Article and Find Full Text PDFObjective: To investigate the incidence and risk factors of portomesenteric venous thrombosis (PVT) after pancreatic cancer surgery with portomesenteric venous resection (PVR).
Summary Background Data: Pancreatic cancer surgery with PVR can be complicated by PVT, but the long-term associations, risk factors, and consequences of PVT have not been clearly elucidated.
Methods: This study included pancreatic cancer patients undergoing any type of pancreatic resection with PVR at the University of Colorado Hospital between January 2012 and June 2023.
Objective: Ampullary neoplastic lesions can be resected by endoscopic papillectomy (EP) or transduodenal surgical ampullectomy (TSA) while pancreaticoduodenectomy is reserved for more advanced lesions. We present the largest retrospective comparative study analysing EP and TSA.
Design: Of all patients in the database, lesions with prior interventions, benign histology advanced malignancy (T2 and more), patients with hereditary syndromes and those undergoing pancreatoduodenectomy were excluded.
Article Synopsis
- Around 5-10% of pancreatic cancer patients don't express CA 19-9, and it's unclear how this affects their cancer severity and prognosis.
- A study analyzed data from 88,749 pancreatic cancer patients, finding that non-expressors had a higher chance of distant metastasis and a shorter median overall survival compared to those with normal CA 19-9 levels.
- The findings suggest that patients who are non-expressors of CA 19-9 might need different diagnostic approaches and more aggressive treatment strategies.